320 related articles for article (PubMed ID: 10337378)
1. Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy.
Bookman MA
Oncologist; 1999; 4(2):87-94. PubMed ID: 10337378
[TBL] [Abstract][Full Text] [Related]
2. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
3. New options for the treatment of advanced ovarian cancer.
Dunton CJ
Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-2-S5-11. PubMed ID: 9122739
[TBL] [Abstract][Full Text] [Related]
4. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
5. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
Meier W; du Bois A; Reuss A; Kuhn W; Olbricht S; Gropp M; Richter B; Lück HJ; Kimmig R; Pfisterer J
Gynecol Oncol; 2009 Aug; 114(2):199-205. PubMed ID: 19446314
[TBL] [Abstract][Full Text] [Related]
6. Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents.
Ozols RF
J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S60-73. PubMed ID: 19780247
[TBL] [Abstract][Full Text] [Related]
7. Weekly topotecan for recurrent platinum resistant ovarian cancer.
Abushahin F; Singh DK; Lurain JR; Grendys EC; Rademaker AW; Schink JC
Gynecol Oncol; 2008 Jan; 108(1):53-7. PubMed ID: 17904208
[TBL] [Abstract][Full Text] [Related]
8. [Recurrent and 2nd line therapy in ovarian carcinoma: an overview of conventional systemic therapy modalities].
du Bois A; Lück HJ; Meerpohl HG
Zentralbl Gynakol; 1997; 119(7):299-323. PubMed ID: 9340970
[TBL] [Abstract][Full Text] [Related]
9. Management of relapsed/refractory epithelial ovarian cancer: current standards and novel approaches.
Lin H; Changchien CC
Taiwan J Obstet Gynecol; 2007 Dec; 46(4):379-88. PubMed ID: 18182343
[TBL] [Abstract][Full Text] [Related]
10. Haematological evaluation of weekly therapy with topotecan for the treatment of recurrent ovarian cancer resistant to platinum-based therapy.
Largillier R; Valenza B; Ferrero JM; Novo C; Creisson A; Lesbats G; Mari V; Hebert C; Chamorey E
Oncology; 2007; 73(3-4):177-84. PubMed ID: 18418010
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinoma.
Gronlund B; Hansen HH; Høgdall C; Engelholm SA
Cancer; 2002 Oct; 95(8):1656-62. PubMed ID: 12365013
[TBL] [Abstract][Full Text] [Related]
12. [Early results of topotecan therapy in patients with recurrent ovarian cancer].
Lehoczky O; Bagaméri A; Lehoczky G; Pulay T
Orv Hetil; 2002 Apr; 143(16):825-8. PubMed ID: 12053883
[TBL] [Abstract][Full Text] [Related]
13. Extending the platinum-free interval with a non-platinum therapy in platinum-sensitive recurrent ovarian cancer. Results from the SOCRATES Retrospective Study.
Pignata S; Ferrandina G; Scarfone G; Scollo P; Odicino F; Selvaggi L; Katsaros D; Frigerio L; Mereu L; Ghezzi F; Manzione L; Lauria R; Breda E; Marforio G; Ballardini M; Lombardi AV; Sorio R; Tumolo S; Costa B; Magni G; Perrone F; Favalli G;
Oncology; 2006; 71(5-6):320-6. PubMed ID: 17878745
[TBL] [Abstract][Full Text] [Related]
14. Phase II evaluation of 3-day topotecan with cyclophosphamide in the treatment of recurrent ovarian cancer.
Hanjani P; Nolte S; Shahin MS
Gynecol Oncol; 2002 May; 85(2):278-84. PubMed ID: 11972388
[TBL] [Abstract][Full Text] [Related]
15. Topotecan and carboplatin in patients with platinum-sensitive recurrent ovarian cancer. Results of a multicenter NOGGO: phase I/II study.
Koensgen D; Stengel D; Belau A; Klare P; Oskay-Oezcelik G; Steck T; Camara O; Mustea A; Sommer H; Coumbos A; Bogenrieder T; Lichtenegger W; Sehouli J;
Cancer Chemother Pharmacol; 2008 Aug; 62(3):393-400. PubMed ID: 17922272
[TBL] [Abstract][Full Text] [Related]
16. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer.
Gordon AN; Tonda M; Sun S; Rackoff W;
Gynecol Oncol; 2004 Oct; 95(1):1-8. PubMed ID: 15385103
[TBL] [Abstract][Full Text] [Related]
17. Treatment options in patients with recurrent ovarian cancer.
Gadducci A; Conte P; Cianci C; Negri S; Genazzani AR
Anticancer Res; 2001; 21(5):3557-64. PubMed ID: 11848523
[TBL] [Abstract][Full Text] [Related]
18. Phase II evaluation of 24-h continuous infusion topotecan in recurrent, potentially platinum-sensitive ovarian cancer: A Gynecologic Oncology Group study.
Markman M; Blessing JA; Alvarez RD; Hanjani P; Waggoner S; Hall K
Gynecol Oncol; 2000 Apr; 77(1):112-5. PubMed ID: 10739699
[TBL] [Abstract][Full Text] [Related]
19. [Chemosensitivity testing of topotecan as second-line agent in chemotherapy of ovarian cancer].
Qian XL; Peng ZL; Liu SL
Ai Zheng; 2003 Dec; 22(12):1352-4. PubMed ID: 14693068
[TBL] [Abstract][Full Text] [Related]
20. Phase II evaluation of topotecan and navelbine in patients with recurrent ovarian, fallopian tube or primary peritoneal cancer.
Herzog TJ; Powell MA; Rader JS; Gibb RK; Lippmann L; Coleman RL; Mutch DG
Gynecol Oncol; 2008 Dec; 111(3):467-73. PubMed ID: 18834619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]